ReviewFrontiers in pharmacology2025
Natural products modulating MAPK for CRC treatment: a promising strategy.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Anticancer Effects of Cucurbitacin B and Meleagrin Associated with TYRO3 Downregulation in Colorectal Cancer Cells.International journal of molecular sciences · 2026Article
- Integrating network pharmacology, molecular docking, and experimental verification to investigate the mechanism of baicalein in colorectal cancer.Journal of gastrointestinal oncology · 2026Article
- Unveiling the Influence of Polyphenols on Mitogen-activated Protein Kinases in Cancer.Cell biochemistry and biophysics · 2026Review
- Synthesis and Characterization of Sulfonamide-Schiff Bases, and Investigation of Cytotoxic, Antioxidant, HDAC, and Apoptotic Activities in Human Colon Cancer Cells (DLD-1 and HT-29).Archiv der Pharmazie · 2026Article
- Multifaceted Anticancer Activity of Flavanone/Chromanone Intermediates for Five-Membered Heterocyclic Derivatives: Targeting Oxidative Stress, Apoptosis, and MAPK Signaling in Colorectal Cancer.Molecules (Basel, Switzerland) · 2026Article
- Targeted phytotherapy: essential oils, multi-target cancer action & nanodelivery.Frontiers in oncology · 2026Review
- Crinis Carbonisatus-Derived Carbon Dot Suspension Alleviates Temporal Lobe Epilepsy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Hybrid chalcone-pyrazoline derivatives: synthesis and in silico evaluation for anticancer potential.Future medicinal chemistry · 2025Article
- Neochlorogenic acid inhibits gastric cancer cell growth through apoptosis and cell cycle arrest.Translational cancer research · 2025Article
- Article
- Andrographolide potentiates anti-tumor immunity in colorectal cancer (CRC) by targeting voltage-dependent anion channel (VDAC) and activating the cGAS-STING axis.Journal of gastrointestinal oncology · 2025Article
- Importance of Advanced Detection Methodologies from Plant Cells to Human Microsystems Targeting Anticancer Applications.International journal of molecular sciences · 2025Review
- The Cytotoxic Activity of Secondary Metabolites from Marine-DerivedMarine drugs · 2025Review
- Advances in intestinal flora for the development, diagnosis and treatment of CRC.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a common malignant tumor of the digestive system, and the pathogenic mechanism is still unclear, mostly related to genetics, immunity, inflammation, and abnormal activation of tumor-related signaling pathways. MAPK belongs to the Ser/Thr kinase family, which plays an important role in complex cellular programs such as the regulation of cell proliferation, differentiation, apoptosis, angiogenesis, and tumor metastasis. Increasing evidence supports that MAPK activation is highly correlated with the risk of CRC. Targeting MAPK may be a therapeutic strategy, and natural products show great therapeutic potential in regulating MAPK-related proteins. In this paper, we searched PubMed, Web of Science and CNKI databases with keywords "colorectal cancer, natural products, MAPK pathway, ERK, P38, JNK" for relevant studies in the last 14 years from 2010 to 2024. This work retrieved 47 studies, aiming to provide new therapeutic strategies for CRC patients and lay the foundation for new drug development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.